Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.
The minimal adverse effects of cognitive behavioral therapy (CBT) and its efficacy compared with medication have led to its recommendation as a first-line treatment for chronic insomnia, but access issues remain, said Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy.
Transcript
Can you speak on the emergence of CBT for chronic insomnia?
Emergence of CBT for chronic insomnia (CBT-I) goes back a little bit. So, when I look at guidelines from 2016, 2017, or even earlier guidelines than that, CBT-I is the first-line treatment for a few reasons.
One, it's been shown to be just as effective as medications are. And 2, there's a lot less side effects, and some would even say no side effects at all. Others say that for some people, their insomnia gets a little worse before it gets better, but other than that, there's no other systemic effects or side effects like there are with medications.
So, due to these reasons, CBT-I is promoted by the guidelines, the governing bodies, physicians, providers, so that's why there's been such an emergence of this type of therapy. The biggest issue really is access. We know CBT-I works, but there's not many providers specifically trained in how to administer CBT-I, so that's one of the biggest barriers: access.
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Read More
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More